Propranolol

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433440 Investigational agents for treatment of traumatic brain injury

A hyper-adrenergic state has long been demonstrated in those patients with severe TBI and is associated with poor outcomes [95]. One strategy to decrease sympathetic hyperactivity is pharmacologic intervention with beta (β)-blockade [96]. In pre-clinical mouse models, propranolol reduces brain edema, increases cerebral perfusion, decreases cerebral hypoxia, and improves neurologic outcomes [97]. The DASH (Decreasing adrenergic or sympathetic hyperactivity after TBI, NCT01322048) study is the first randomized, double-blinded, placebo-controlled trial powered to determine safety and outcomes associated with adrenergic blockade in patients with severe TBI [98]. If the study results in positive trends, this could provide pilot evidence for a larger multicenter randomized clinical trial